New combo therapy aims to control advanced breast cancer after other treatments fail

NCT ID NCT05530057

Recruiting now Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a trastuzumab biosimilar (SB3) to the chemotherapy drug eribulin helps control advanced HER2-positive breast cancer better than eribulin alone. It includes 180 adults whose cancer has spread or cannot be removed and who have already tried at least two prior HER2-targeted treatments. The main goal is to see how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Seoul National University Hospital
RECRUITING

Seoul, South Korea

Contact

Contact

Contact Phone: •••-•••-••••